Sinovac cuts full-year revenue forecast

Sinovac Biotech shares fell 10 percent Monday, a day after the vaccine manufacturer cut its full-year revenue forecast for the second time, citing continued weakness in Chinese demand for vaccines. "The vaccine market in China is experiencing a much longer than originally expected demand weakness in the market following the unfounded media reports about vaccine safety in China's Shanxi province," the company says in a release. Sinovac release | Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.